FIGURE 1 from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study

Summary of reductions in tumor size and durations of PFS or response. A, Best percentage change from baseline in target lesions (green bars) and PFS in responding patients (gray bars) in the urothelial carcinoma cohorts.aB, DOR in responding patients and change in tumor size over time in all patients in the urothelial carcinoma cohorts. C, Best percentage change from baseline in target lesions (green bars) and PFS in responding patients (gray bars) in the NSCLC cohorts. TMB high represents >10 mut/Mb. In urothelial carcinoma cohorts, PD-L1–positive status was defined using an algorithm that combines assessments of PD-L1 staining on tumor and immune cells, which were scored by pathologists (30); in NSCLC cohorts, PD-L1–positive status was defined as PD-L1 expression on ≥1% of tumor cells. PD-L1, programmed death-ligand 1; TMB, tumor mutational burden; FGFR, fibroblast growth factor receptor. aTwo patients with no postbaseline tumor assessments who were receiving avelumab 1,200 mg were excluded.